Detalhe da pesquisa
1.
Safety, tolerability, and activity of the active C1s antibody riliprubart in cold agglutinin disease: a phase 1b study.
Blood
; 143(8): 713-720, 2024 Feb 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38085846
2.
Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial.
Blood
; 140(9): 980-991, 2022 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35687757
3.
COVID-19 vaccine safety and immunogenicity in patients with cold agglutinin disease receiving concomitant sutimlimab.
Am J Hematol
; 99(4): 789-791, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38385639
4.
Sutimlimab provides clinically meaningful improvements in patient-reported outcomes in patients with cold agglutinin disease: Results from the randomised, placebo-controlled, Phase 3 CADENZA study.
Eur J Haematol
; 110(3): 280-288, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-36403132
5.
Sustained sutimlimab response for 3 years in patients with cold agglutinin disease: A phase I, open-label, extension trial.
Br J Haematol
; 198(4): e59-e62, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35655238
6.
Sutimlimab, an investigational C1s inhibitor, effectively prevents exacerbation of hemolytic anemia in a patient with cold agglutinin disease undergoing major surgery.
Am J Hematol
; 97(2): E51-E54, 2022 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34778998
7.
Long-term sutimlimab improves quality of life for patients with cold agglutinin disease: CARDINAL 2-year follow-up.
Blood Adv
; 7(19): 5890-5897, 2023 10 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37459203
8.
Efficacy and Safety of Insulin Glargine 300 Units/mL (Gla-300) Versus Insulin Glargine 100 Units/mL (Gla-100) in Children and Adolescents (6-17 years) With Type 1 Diabetes: Results of the EDITION JUNIOR Randomized Controlled Trial.
Diabetes Care
; 43(7): 1512-1519, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32430458
9.
Safety, Immunogenicity, and Glycemic Control of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Also Using Insulin Glargine: 12-Month Results from the GEMELLI 1 Trial.
Diabetes Technol Ther
; 22(7): 516-526, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32068436
10.
Efficacy and Safety of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Treated for 26 Weeks with Multiple Daily Injections in Combination with Insulin Glargine: A Randomized Open-Label Trial (GEMELLI 1).
Diabetes Technol Ther
; 22(2): 85-95, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31804851
11.
Efficacy and Safety of Flexible Versus Fixed Dosing Intervals of Insulin Glargine 300 U/mL in People with Type 2 Diabetes.
Diabetes Technol Ther
; 18(4): 252-7, 2016 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-26840338
12.
Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 Trial.
Diabetes Care
; 39(8): 1318-28, 2016 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-27222510
13.
New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2).
Diabetes Care
; 37(12): 3235-43, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25193531